Go to:
Logótipo
Você está em: Start > Publications > View > Statins and oxidative stress in chronic heart failure
Map of Premises
Principal
Publication

Statins and oxidative stress in chronic heart failure

Title
Statins and oxidative stress in chronic heart failure
Type
Article in International Scientific Journal
Year
2016
Authors
Costa, S
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Marta R Couto
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Albino Teixeira, A
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Sousa, T
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Vol. 35
Pages: 41-57
ISSN: 0870-2551
Other information
Authenticus ID: P-00K-0N4
Abstract (EN): Statins are the most commonly prescribed drugs for the treatment of dyslipidemia. They are also recommended in primary and secondary prevention of cardiovascular disease. In addition to decreasing cholesterol synthesis, statins interfere with the synthesis of isoprenoid intermediates, which may explain many of their pleiotropic properties, including their antioxidant effects. Oxidative stress is defined as an imbalance between the synthesis of reactive oxygen species and their elimination by antioxidant defense systems, with a prevailing pro-oxidant status that results in macromolecular damage and disruption of cellular redox signaling. Reactive oxygen species interfere with various processes that affect cardiac structure and function, contributing to the contractile dysfunction, myocardial hypertrophy and fibrosis observed in the pathophysiology of heart failure. By regulating several molecular pathways that control nicotinamide adenine dinucleotide phosphate oxidase and endothelial nitric oxide synthase activity, statins help restore redox homeostasis. These drugs also contribute to the control of inflammation and appear to have a protective role in various diseases. The results of observational studies and clinical trials with statins in heart failure have not been consensual. This review aims to analyze the role of oxidative stress in heart failure and the molecular mechanisms underlying statins' antioxidant properties. It also examines current scientific evidence on the use of these drugs as a specific treatment for heart failure.
Language: Portuguese
Type (Professor's evaluation): Scientific
No. of pages: 17
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

The phenomenon of migration and cardiovascular risk factors (2018)
Another Publication in a National Scientific Journal
Campelo, M
Stabbed in the right place: The millimetric line between luck and disaster; [Apunhalado no sítio certo: a linha milimétrica entre a sorte e o desastre] (2023)
Another Publication in a National Scientific Journal
Amaral Marques, C; Mil Homens, F; Resende, CX; Fernandes, J; Gouveia, D; Pinho, P; Macedo, F
Social media use by cardiovascular healthcare professionals: Exploring a challenging and ever evolving frontier (2023)
Another Publication in a National Scientific Journal
Vilela, EM; José Pedro Nunes
Smoking in Portugal: Where do we stand today? (2019)
Another Publication in a National Scientific Journal
Pereira, AM
Sacubitril-valsartan in the real world: From theory to clinical practice (2018)
Another Publication in a National Scientific Journal
Fontes-Carvalho R

See all (628)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Medicina Dentária da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-15 at 19:27:42 | Privacy Policy | Personal Data Protection Policy | Whistleblowing | Electronic Yellow Book